Oncothyreon-Merck Serono lung cancer drug testing to continue – Puget Sound Business Journal (Seattle) (blog)

by lowes1 on September 25, 2013


Economic Times
Oncothyreon-Merck Serono lung cancer drug testing to continue
Puget Sound Business Journal (Seattle) (blog)
Oncothyreon Inc. said its partner Merck Serono will continue development of the lung cancer drug tecemotide, and shares in the Bellevue biotech soared in Wednesday pre-trading. Tecemotide, which is also known as L-BLP25 and was formerly known as 
Merck Serono to Continue Development of Oncothyreon Lung Cancer Drug4-traders (press release)
Merck KGaA to continue testing cancer vaccineEconomic Times
Merck KGaA doubles down on Oncothyreon's failed cancer vaccineFierceBiotech
PharmaTimes -MarketWatch
all 14 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: